Switch theme
Sign up to access all valuation multiples
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
2021
13
Last FY Revenue n/a
Last FY EBITDA -$10.6M
$26.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, FibroBiologics achieved revenue of n/a and an EBITDA of -$10.6M.
FibroBiologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See FibroBiologics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$10.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$15.2M | XXX | -$13.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$13.8M | XXX | -$11.2M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, FibroBiologics's stock price is $1.
FibroBiologics has current market cap of $27.8M, and EV of $26.2M.
See FibroBiologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.2M | $27.8M | XXX | XXX | XXX | XXX | $-0.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, FibroBiologics has market cap of $27.8M and EV of $26.2M.
FibroBiologics's trades at n/a EV/Revenue multiple, and -2.5x EV/EBITDA.
Equity research analysts estimate FibroBiologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
FibroBiologics has a P/E ratio of -2.0x.
See valuation multiples for FibroBiologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $27.8M | XXX | $27.8M | XXX | XXX | XXX |
| EV (current) | $26.2M | XXX | $26.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.5x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -1.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.0x | XXX | -2.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFibroBiologics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
FibroBiologics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
FibroBiologics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for FibroBiologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
FibroBiologics acquired XXX companies to date.
Last acquisition by FibroBiologics was XXXXXXXX, XXXXX XXXXX XXXXXX . FibroBiologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was FibroBiologics founded? | FibroBiologics was founded in 2021. |
| Where is FibroBiologics headquartered? | FibroBiologics is headquartered in United States of America. |
| How many employees does FibroBiologics have? | As of today, FibroBiologics has 13 employees. |
| Who is the CEO of FibroBiologics? | FibroBiologics's CEO is Mr. Peter O’Heeron. |
| Is FibroBiologics publicy listed? | Yes, FibroBiologics is a public company listed on NAS. |
| What is the stock symbol of FibroBiologics? | FibroBiologics trades under FBLG ticker. |
| When did FibroBiologics go public? | FibroBiologics went public in 2024. |
| Who are competitors of FibroBiologics? | Similar companies to FibroBiologics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of FibroBiologics? | FibroBiologics's current market cap is $27.8M |
| Is FibroBiologics profitable? | Yes, FibroBiologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
